Default company panoramic image

ADispell, Inc

A platform technology for drug development has produced positive in vivo results treating cognition/memory loss while also treating anxiety.

  • Stage Product In Development
  • Industry Biotechnology
  • Location United States
  • Currency USD
  • Founded January 2009
  • Employees 4
  • Incorporation Type C-corp
  • Website

Company Summary

ADispell is dedicated to rapidly advancing a new therapeutic platform technology to treat devastating memory-loss conditions while also positively affecting anxiety. We have 3 lead compounds. The compounds produced positive in vivo results for memory loss and improved learning, successfully crossed the blood-brain barrier, is a vasodilator, and is safe. Our development work is well advanced and involves a new approach that favors neuron health.


  • Default avatar
    Stephen Curry

    leverages research and commercialization experience to steer the project. Dr. Curry has a pharma academic and industry background with 10 years in R&D at Astra Zeneca where he evaluated technologies from outside companies.He previously founded PharmaNova a development company with treatment for menopausal hot flashes that completed clinical trial and is expected to sell in 2014

  • Default avatar
    George Hess
    Chief Scientist

    Dr Hess has been a professor of Chemistry and Biochemistry at Cornell University for 40 years. He is an elected member of National Academy of Sciences and an Elected Fellow of the American Academy of Microbiology, Biophysics Society, and the American Academy of Arts and Sciences. Dr Hess has worked in this research area for the last fifteen years and has developed a number of innovations. His work is the basis for the formation of ADispell.

  • Default avatar
    Brad Gouldthorpe

    Brad has filled finance, marketing, business development, and lead roles with start-up companies. He has worked at Kodak and Xerox where he led strategy and new product launch efforts. He has since been president of a start-up company and has worked for the last nine years as a hands-on resource for start-ups in markets such as medical technology and nanotechnology regarding commercialization, launch, marketing, and profitability.

  • Default avatar
    Susan Coombs
    Project Director

    Ms. Coombs started her career overseas participating and overseeing research programs in academic environments. Susan started working with Dr. Hess in the 1970s and has grown her responsibilities to oversee that work gets accomplished in the lab and that experimental results are valid. Susan directs our in vitro program at ADispell.


  • Default avatar
    Montieth Estes
    Default avatar
    Ciaschi, Dietershagen, Little, Mickelson & Co.